Is Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients?

Micro-Abstract Although there has been an increase in overall and progression-free survival with the use of novel targeted therapies in metastatic renal cell carcinoma (mRCC) in recent times, predictive markers to determine which patients would benefit from tyrosine kinase inhibitor therapies are ne...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical genitourinary cancer 2015-12, Vol.13 (6), p.548-554
Hauptverfasser:	Bozkurt, Oktay, Hacıbekiroglu, Ilhan, Kaplan, Muhammet Ali, Duzkopru, Yakup, Uysal, Mukremin, Karaca, Halit, Berk, Veli, Inanc, Mevlude, Duran, Ayse Ocak, Ozaslan, Ersin, Ucar, Mahmut, Ozkan, Metin
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - pathology Female Hematology, Oncology and Palliative Medicine Humans Indoles - therapeutic use Kidney Neoplasms - drug therapy Kidney Neoplasms - pathology Late recurrence Male Middle Aged Neoplasm Metastasis Neoplasm Recurrence, Local - diagnosis Prognosis Prognostic factor Pyrroles - therapeutic use Renal cell carcinoma Sunitinib Survival Survival Analysis Treatment Outcome Turkey Urology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Micro-Abstract Although there has been an increase in overall and progression-free survival with the use of novel targeted therapies in metastatic renal cell carcinoma (mRCC) in recent times, predictive markers to determine which patients would benefit from tyrosine kinase inhibitor therapies are needed. The late recurrence might be a predictive marker for response to sunitinib treatment in patients with mRCC.
ISSN:	1558-7673 1938-0682
DOI:	10.1016/j.clgc.2015.07.005